Cas:46917-20-8 2,2′-[(4-Vinylbenzyl)imino]diacetic acid manufacturer & supplier

Chemical Name:2,2′-[(4-Vinylbenzyl)imino]diacetic acid

CAS.NO:46917-20-8

Synonyms:2,2′-[(4-Vinylbenzyl)imino]diacetic acid;Glycine, N-(carboxymethyl)-N-[(4-ethenylphenyl)methyl]-

Molecular Formula:C₁₃H₁₅NO₄

Molecular Weight:249.262

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:454.4±40.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.612

PSA:77.84000

Exact Mass:249.100113

LogP:1.99

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,2′-[(4-Vinylbenzyl)imino]diacetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Glycine, N-(carboxymethyl)-N-[(4-ethenylphenyl)methyl]- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Glycine, N-(carboxymethyl)-N-[(4-ethenylphenyl)methyl]- Use and application,2,2′-[(4-Vinylbenzyl)imino]diacetic acid technical grade,usp/ep/jp grade.

Related News: ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. 2,2′-[(4-Vinylbenzyl)imino]diacetic acid manufacturer As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2,2′-[(4-Vinylbenzyl)imino]diacetic acid supplier From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity. 2,2′-[(4-Vinylbenzyl)imino]diacetic acid vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2,2′-[(4-Vinylbenzyl)imino]diacetic acid factory Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.